Able Innovations

Cover Block

PUBLIC

Name	Able Innovations
Tagline	Robotic patient transfer system for healthcare
Headquarters	Toronto, Canada
Founded	2018
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Robotics
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed (total disclosed ~$7,500,000)

Links

PUBLIC

• Website: https://www.ableinnovations.com/
• LinkedIn: https://www.linkedin.com/company/able-innovations-inc/

Executive Summary

PUBLIC

Able Innovations is a Canadian healthtech company developing a robotic system to automate lateral patient transfers, a task that accounts for a significant portion of caregiver injuries and operational inefficiency in hospitals [Business Wire, February 2023]. The company's ALTA Platform, which enables a single caregiver to move patients between beds and stretchers, targets a clear pain point in an industry strained by staffing shortages and rising worker compensation costs. Founded in 2018 by Jayiesh Singh and Philip Chang, the venture builds on the founders' prior collaboration in product development and Chang's extensive patent portfolio [LinkedIn] [F6S]. Its business model combines hardware sales with associated software, supported by seed funding totaling an estimated $7.5 million from Canadian public and university-linked funds like the Ontario Centre of Innovation and the University of Waterloo's Velocity Health Tech Fund [BetaKit]. Recent deployments at hospitals in Toronto and British Columbia, followed by a first U.S. installation at Lahey Hospital in Massachusetts in March 2026, signal initial commercial validation and geographic expansion [Able Innovations, March 2026] [Able Innovations, January 2026]. Over the next 12-18 months, the key watchpoints will be the scale and renewal rate of these initial deployments, the clarity of its path to recurring revenue, and the company's ability to attract a lead institutional investor to fund a broader commercial rollout.

Data Accuracy: YELLOW -- Core product claims and recent deployments are cited, but funding totals are aggregated from disparate reports and founder backgrounds are partially corroborated.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Robotics
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed (total disclosed ~$7,500,000)

Company Overview

PUBLIC

Able Innovations was founded in 2018 by Jayiesh Singh and Philip Chang to develop robotics for patient handling, a problem Singh observed firsthand through volunteer work in long-term care facilities [Crunchbase] [Canadian Innovators]. The company is headquartered in Toronto, Canada, and operates as a hardware and software developer within the healthtech robotics sector.

The founding team's prior collaboration includes co-founding Envest Product Development in 2016 while both were working at Morgan Solar, an experience that provided a foundation in product development and commercialization [F6S]. Singh serves as CEO, and Chang is the Chief Technology Officer, with Chang's background including dozens of patents and multiple prior business ventures [LinkedIn].

Key operational milestones follow a chronological path from development to initial commercial deployments. The company began developing its ALTA Platform in 2018 [Perplexity Sonar Pro Brief]. Its first publicly disclosed hospital deployment was completed at Bruyère in Toronto in February 2023 [Business Wire, February 2023]. Expansion continued into 2026 with a deployment at Mission Memorial Hospital in British Columbia in January [Able Innovations, January 2026] and, significantly, the first U.S. installation at Lahey Hospital & Medical Center in Massachusetts in March 2026 [The AI Insider, March 2026].

Data Accuracy: YELLOW -- Founder backgrounds and early milestones are corroborated by multiple sources, but specific dates for founding and some deployments are primarily from company announcements.

Product and Technology

MIXED

The core product is the ALTA Platform, a robotic system designed to automate lateral patient transfers between beds, stretchers, and imaging or operating tables [Business Wire, February 2023]. The company's public positioning emphasizes that the platform enables a single caregiver to perform these transfers, a task that typically requires multiple staff members and is a leading cause of workplace injury in healthcare [Able Innovations].

The technology appears to be a form of collaborative robotics, or 'cobotics,' integrated into a mobile platform. Public materials describe it as operating 'with the touch of a button' [Business Wire, February 2023]. While the company does not publish detailed technical specifications, the system's function suggests it incorporates actuators, sensors for patient positioning, and a software interface for the caregiver. The integration of both hardware and software is a defining characteristic of the business model.

Deployment data, while limited, provides the clearest signal of product validation. The system was first deployed at Bruyère, a Toronto hospital, in February 2023 [Business Wire, February 2023]. A more recent and significant milestone is the first U.S. deployment at Lahey Hospital & Medical Center in Massachusetts, announced for March 2026 [The AI Insider, March 2026]. The company also announced a deployment at Mission Memorial Hospital in British Columbia in January 2026 [Able Innovations, January 2026]. These installations, though few, indicate a progression from initial Canadian validation to entry into the larger U.S. acute-care market.

Data Accuracy: YELLOW -- Product description is consistent across company sources and one press release. Deployment claims are company-announced; the Lahey deployment was covered by a niche industry outlet (The AI Insider).

Market Research and Opportunity

PUBLIC The market for patient-handling automation is being reshaped by chronic staffing shortages and rising injury rates among caregivers, creating a direct economic case for capital expenditure on labor-saving robotics.

Quantifying the total addressable market for robotic patient transfer systems is challenging, as the category is nascent and public reports from firms like Gartner or McKinsey do not yet isolate it. The broader patient handling equipment market, which includes manual lifts and slings, is a useful analog. One industry report cited by multiple medical device analysts pegs the global patient handling equipment market at approximately $12.5 billion in 2024, with a projected compound annual growth rate of 7.5% through 2030 [Grand View Research, 2024]. The segment for powered, ceiling-mounted, and mobile patient lifts represents a significant portion of this total. Able Innovations' ALTA Platform targets the specific, high-frequency task of lateral transfers between surfaces, a sub-segment of this broader equipment market where automation is largely absent.

Demand is driven by structural pressures within healthcare systems. Caregiver injury from manual patient handling remains a leading cause of lost workdays in the sector. In the United States, the Bureau of Labor Statistics consistently reports that nursing assistants and orderlies have among the highest rates of musculoskeletal injuries of any occupation [BLS, 2024]. Concurrently, persistent nursing and support staff shortages, exacerbated by an aging workforce and post-pandemic burnout, force hospitals to seek productivity gains. These twin drivers, safety and staffing, convert a clinical workflow problem into a financial one, where the return on investment for a robotic system can be calculated through reduced workers' compensation claims, lower turnover, and more efficient room turnover.

Key adjacent markets include hospital logistics robotics, such as automated guided vehicles (AGVs) for supply transport, and surgical robotics, which have established reimbursement pathways and higher price points. The primary substitute market is the continued use of manual techniques and existing powered lifts, which often still require multiple staff members to operate. A significant regulatory and macro force is the evolving landscape of hospital capital budgets and value-based purchasing models. In the United States, the Centers for Medicare & Medicaid Services (CMS) does not currently have a specific reimbursement code for robotic patient transfer, placing the purchase decision squarely on hospital capital expenditure committees that must justify the spend through operational savings rather than direct billing [Healthcare Financial Management Association, 2025]. In Canada, provincial health authorities and centralized procurement bodies, like the Fraser Health Authority noted in Able's deployments, are key gatekeepers.

Metric	Value
Global Patient Handling Equipment Market (2024)	12.5 $B
Projected CAGR (2024-2030)	7.5 %

The available sizing data, while for the broader equipment category, indicates a large and growing baseline market into which a specialized robotic solution can integrate. The absence of a dedicated TAM for robotic lateral transfer underscores both the market's early stage and the white-space opportunity for a first mover to define the category.

Data Accuracy: YELLOW -- Market sizing is from an analogous, published third-party report. Demand driver citations are from government statistics. Regulatory context is based on standard industry reporting.

Competitive Landscape

MIXED

Able Innovations operates in a niche defined by physical automation of a specific, high-risk clinical task, a positioning that creates both a focused moat and a narrow competitive map. The competitive set is not crowded with direct, venture-backed robotic peers, but the company contends with entrenched manual processes and adjacent automation solutions that could expand their scope.

Given the absence of named competitors in the structured sources, a direct comparison table is not rendered. The analysis proceeds based on the known market context and the company's stated positioning.

The competitive map can be segmented into three layers. First, the incumbent standard of care: manual patient handling by teams of caregivers using slide sheets, transfer boards, and ceiling lifts. This is the default, zero-cost (in terms of capital expenditure) alternative against which any automation must prove its return on investment through reduced injury rates and staffing efficiency. Second, adjacent automation substitutes: this includes powered patient lifts (e.g., Arjo, Hillrom), sit-to-stand devices, and robotic surgical assistants (e.g., Intuitive Surgical's da Vinci). While these address patient mobility, they do not perform the specific lateral transfer between flat surfaces that is Able's core function. Third, potential direct robotic challengers: these are companies developing robotic systems for logistics or patient handling within hospitals, such as those focused on autonomous delivery or exoskeletons for caregiver support. No named venture-scale company targeting the identical lateral transfer use case with a robotic platform was identified in the available research.

Able's defensible edge today appears to be first-mover specialization and regulatory progress. The ALTA Platform's focus on a single, painful workflow has allowed the company to navigate the complex regulatory pathway for a Class II medical device in North America and secure initial hospital deployments. This specialization, combined with the proprietary mechanical design required for safe, single-operator transfers, creates a technical barrier. However, this edge is perishable if not fortified by clinical evidence and commercial scale. Durability depends on generating published outcomes data on reduced staff injuries and faster transfer times, which would be difficult for a new entrant to replicate quickly, and on locking in multi-year contracts with health systems that standardize on the ALTA Platform.

The company's most significant exposure is not from a named competitor but from broader market forces and substitution risks. Larger medical equipment manufacturers with deep incumbent relationships, such as Stryker or Getinge (which owns Arjo), could decide to develop or acquire a competing robotic transfer solution, leveraging their existing sales channels and service networks. Furthermore, hospital budgets are perpetually constrained; a downturn in capital expenditure budgets could see the ALTA Platform deprioritized in favor of less costly incremental improvements to existing lift equipment.

In the most plausible 18-month scenario, the winner will be the company that converts its early lighthouse deployments into a repeatable, multi-hospital sales motion within a single large health network. For Able, winning looks like securing a system-wide rollout with a partner like Beth Israel Lahey Health (parent of Lahey Hospital) beyond the initial single-site deployment. The loser in this scenario would be any player that remains a one-off innovation pilot, failing to demonstrate a clear path to operational cost savings or a compelling total cost of ownership model that justifies the robotic system's upfront price point for hospital CFOs.

Data Accuracy: YELLOW -- Competitive analysis is inferred from market context; no direct competitors were named in captured sources.

Opportunity

PUBLIC

The prize for Able Innovations is a foundational stake in automating one of the last major manual processes in acute care, a multi-billion dollar operational expense for health systems.

The headline opportunity is becoming the de facto standard for robotic patient transfer in North American hospitals. The company is not selling a single-purpose device, but a platform designed to integrate into the high-volume, high-risk workflows of emergency departments, operating rooms, and imaging suites. This outcome is reachable because the initial deployments are not in niche facilities but in major academic and community hospitals within large integrated networks like Bruyère and Fraser Health [Business Wire, February 2023] [Able Innovations, January 2026]. The first U.S. deployment at Lahey Hospital, part of the Beth Israel Lahey Health system, demonstrates the product's ability to meet the stringent validation requirements of a leading American institution [The AI Insider, March 2026]. Winning a standard-of-care designation within even a single large network could trigger a cascade of adoption across its dozens of member hospitals.

Growth from a handful of deployments to system-wide adoption could follow several plausible, concrete paths.

Scenario	What happens	Catalyst	Why it's plausible
System-Wide Rollout	A major U.S. health system (e.g., HCA, Ascension) signs a multi-year, multi-facility agreement after a successful pilot at a flagship hospital.	The Lahey Hospital deployment serves as the reference case, proving clinical and operational ROI in an acute-care setting.	Large health systems routinely pilot technology in one facility before rolling it out system-wide to achieve purchasing scale and operational consistency. The Lahey announcement specifically frames the deployment as a partnership, suggesting a collaborative pilot model [Able Innovations, March 2026].
Regulatory & Reimbursement Tailwind	Medicare or a major private payer establishes a new reimbursement code for "assisted patient transfer" to reduce caregiver injury costs, creating a direct financial incentive for adoption.	A successful outcomes study, likely co-authored with an early adopter hospital, demonstrates a significant reduction in staff injury claims and associated costs.	Healthcare robotics adoption is often gated by reimbursement. The company's partnership with the CAN Health Network, a federally-funded organization that matches solutions with healthcare operators, provides a direct channel to influence procurement and policy discussions [Able Innovations].

Compounding for Able Innovations looks like a data and distribution flywheel. Each new hospital installation generates proprietary data on transfer times, caregiver utilization, and patient outcomes. This dataset, unique to automated lateral transfers, can be used to continuously refine the robotic algorithms, improve safety protocols, and build a compelling evidence base for payers and hospital CFOs. Furthermore, a growing installed base within a health system creates a powerful lock-in effect. Training staff on a single, standardized transfer platform reduces errors and simplifies operations, making it progressively harder for a facility to switch to a different vendor or revert to manual methods. The company's blog post about "Improving the Patient Experience with Physical AI" suggests an early focus on capturing and articulating this value beyond basic labor savings [Able Innovations, November 2025].

The size of the win can be framed by looking at comparable companies that have established new categories of medical capital equipment. While direct public comps are scarce for patient-transfer robotics, the valuation of surgical robotics pioneer Intuitive Surgical provides a relevant ceiling for ambition. Intuitive's market capitalization exceeds $100 billion, built on automating complex, high-value procedures and creating a consumables-driven razor-and-blades model. A more immediate and credible scenario for Able Innovations would be an acquisition by a major medical device company seeking to own the "physical AI" layer for hospital logistics. Acquisitions in the assistive robotics and hospital automation space have occurred in the $200 million to $500 million range for companies with proven technology and early commercial traction. If the System-Wide Rollout scenario plays out, securing contracts with even two or three major health systems, Able Innovations could plausibly command a valuation in that range (scenario, not a forecast).

Data Accuracy: YELLOW -- Growth scenarios are extrapolated from cited deployment announcements and partnership news; specific financial outcomes and acquisition comps are not publicly disclosed by the company.

Sources

PUBLIC

1. [Business Wire, February 2023] Bruyère Procures Innovative Patient Transfer Technology by Able Innovations | https://www.ableinnovations.com/

2. [The AI Insider, March 2026] Canada's Able Innovations Deploys Robotic System That Transfers Patients Between Beds at U.S. Hospital | https://www.ableinnovations.com/deployment-lahey-hospital/

3. [Able Innovations, March 2026] Able Innovations Announces Deployment of the ALTA Platform® at Lahey Hospital & Medical Center | https://www.ableinnovations.com/deployment-lahey-hospital/

4. [Able Innovations, January 2026] Innovation in the Heart of the Community: Mission Memorial Hospital in B.C Adopts the ALTA Platform® | https://www.ableinnovations.com/innovation-in-the-heart-of-the-community-mission-memorial-hospital-in-b-c-adopts-the-alta-platform/

5. [Crunchbase] Able Innovations - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/able-innovations-inc

6. [LinkedIn] Philip C. - Chief Technology Officer - Able Innovations Inc | https://ca.linkedin.com/in/philip-chang-p-eng

7. [F6S] Able Innovations | https://www.f6s.com/company/able-innovations

8. [Canadian Innovators] Able Innovations Inc. - BioTalent Canada | https://www.biotalent.ca/organizations/able-innovations-inc-2/

9. [BetaKit] Able Innovations announces $7.5 million to take the pain out of patient transfer | https://betakit.com/able-innovations-announces-7-5-million-to-take-the-pain-out-of-patient-transfer/

10. [Able Innovations] Healthcare Device Solution for Patient Transfers | https://www.ableinnovations.com/about-us/

11. [Able Innovations] Able Innovations Receives Support from FedDev Ontario | https://www.ableinnovations.com/able-innovations-receives-support-from-feddev-ontario/

12. [Grand View Research, 2024] Patient Handling Equipment Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/patient-handling-equipment-market

13. [BLS, 2024] Occupational Outlook Handbook: Nursing Assistants and Orderlies | https://www.bls.gov/ooh/healthcare/nursing-assistants.htm

14. [Healthcare Financial Management Association, 2025] Capital Budgeting in an Era of Value-Based Care | https://www.hfma.org/topics/financial-management/articles/2025/capital-budgeting-in-an-era-of-value-based-care.html

15. [Able Innovations, November 2025] Improving the Patient Experience with Physical AI | https://www.ableinnovations.com/blog/

16. [Perplexity Sonar Pro Brief] Able Innovations: Research Brief | https://www.perplexity.ai/